TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Bacteria in the Mouth and Throat of Healthy Adults Before and After the Administration of Either Levofloxacin or Azithromycin, Both Antibiotic Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* Healthy on the basis of a pre-study physical examination, medical history, and the laboratory results of blood hematology, biochemistry, and urinalysis performed within 24 hours before the first dose~* Renal function tests must be within the normal laboratory reference ranges~* Normotensive with sitting (5 minutes) blood pressure between the range of 90 to 140 mmHg systolic, inclusive, and 50-90 mmHg diastolic, inclusive~* Normal temperature for at least 72 hours. Normal defined as \>36.0 C (96.8 F) to \<37.5 C (99.5 F)~* Weight as defined by BMI range of 18 to 32 kg/m2, inclusive~* Must have read and signed the informed consent document before the first study-related procedure indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.~Exclusion Criteria:~* History of allergy or serious adverse reaction to levofloxacin or any other quinolone or to azithromycin or any other macrolide~* Clinically significant abnormal laboratory values~* Previous systemic antimicrobial therapy within 3 months of Study Entry for any reason~* Hospitalized for any cause within 3 months prior to Study Entry~* Current drug abuse, alcohol abuse, or homelessness~* Requirement for any prescription or non-prescription medication or supplements such as vitamins and herbal supplements, except for paracetamol (acetaminophen) for the treatment of headache and other pain, hormone replacement therapy, and birth control medication upon study entry and during study conduct~* Pregnancy or breastfeeding~* Has received an experimental drug or medical device within the previous 3 months or involvement in any other experimental protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Neuromuscular Blockade on Operating Conditions and Overall Satisfaction During Spinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) physical status I-II adult patients scheduled for elective spinal (cervical or lumbar) surgery under general anesthesia~Exclusion Criteria:~* Pregnancy~* Present medication known to interfere with neuromuscular blockade~* Diseases affecting neuromuscular transmission~* History of hypersensitivity on rocuronium or sugammadex~* Emergent spinal surgery~* Spinal surgeries which have lesions more than 3 spinal levels~* Spinal surgeries which have duration less than 1 hour~* Spinal surgeries which are not performed under prone position~* Spinal surgeries which are not performed under total intravenous anesthesia (TIVA).~* Patients who will have hemodynamic instability (mean blood pressure increase or fall of \> 30% from baseline lasting for more than 5 min) during surgery~* Patients who will have blood loss \> 1 L during surgery~* MEP monitored spinal surgeries

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- deep neuromuscular blockade (Type: EXPERIMENTAL): This arm will be given sufficient dose of rocuronium. In this Arm group, rocuronium will be administered to maintain deep neuromuscular blockade \[NMB\] (train-of-four \[TOF\] count 0, post-tetanic count \[PTC\] of 1-2 twitches) until the end of surgery and the reversal of NMB will be performed by sugammadex 4 mg/kg at the end of surgery'.
- restricted neuromuscular blockade (Type: ACTIVE_COMPARATOR): This arm will not be given sufficient dose of rocuronium. In this Arm group, sugammadex will be administered according to the prescribing indications (4 mg/kg for deep neuromuscular blockade \[NMB\] state or 2 mg/kg for moderate NMB or less) to reverse the NMB 10 min after position change (sugammadex 10 min after position change \[a prone position\]). Thereafter, muscle relaxants will not be injected any more throughout the surgery except the following situations: If the patients show any body movement during surgery or if surgeons express any complaint about muscle tone (the muscle tone: grade 3), rescue rocuronium 5 mg will be administered and the number of body movements and rescue rocuronium administration (dose) will be recorded.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females older than 50 years of age with acute vertebral compression fractures causing significant pain and functional limitations in their daily activities.~Exclusion Criteria:~* primary tumors of bone or evidence of metastasis at the index vertebrae~* pre-existing chronic pain or functional disability unrelated to a vertebral compression fracture which would confound the data analysis~* fracture secondary to a traumatic event~* inability to fully visualize both pedicles of the fractured vertebrae on intraoperative fluoroscopy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Unipedicular kyphoplasty (Type: ACTIVE_COMPARATOR): Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm only vertebral body pedicle was entered to deliver bone cement.
- Bipedicular Kyphoplasty group (Type: ACTIVE_COMPARATOR): Balloon kyphoplasty achieves reduction of the vertebral compression fracture using a balloon tamp inserted into the vertebral body by a transpedicular approach, followed by fixation of the fracture fragments with polymethylmethacrylate (PMMA) bone cement. In this arm two pedicles were entered to deliver bone cement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male or non-pregnant, non-lactating female patients at least 18 years of age~* Diagnosis of moderate to severe AS with prior documented radiologic evidence (X-ray) fulfilling the Modified New York criteria for AS (1984)~* Patients should have been on NSAIDs with an inadequate response~* Patients who are regularly taking NSAIDs as part of their AS therapy are required to be on a stable dose~* Patients who have been on an anti-TNFα agent (not more than one) must have experienced an inadequate response~Exclusion criteria:~* Chest X-ray with evidence of ongoing infectious or malignant process~* Patients with total ankylosis of the spine~* Patients previously treated with any biological immunomodulating agents except for those targeting TNFα~* Previous treatment with any cell-depleting therapies~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 10 mg/kg i.v. / 75 mg s.c. (Type: EXPERIMENTAL): Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
- Secukinumab 10 mg/kg i.v. / 150 mg s.c. (Type: EXPERIMENTAL): Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.
- Placebo (Type: PLACEBO_COMPARATOR): Three i.v. infusions: at Baseline and weeks 2 and 4, followed by one s.c. injection every four weeks until the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of the Oral Care With Vaccines for Pneumonia in Elderly; Going Home Together Both Physician and Dentist

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The residents or an agent who understand the purpose of this study and give informed consent.~Exclusion Criteria:~* The residents contraindicated to vaccine

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Oral care and vaccines (Type: EXPERIMENTAL): Oral care and pneumococcal plus influenza vaccines
- Vaccine (Type: ACTIVE_COMPARATOR): Influenza vaccine only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent form voluntarily.~* Male or female，age over 18 years old (inclusive) and not more than 75 years old (inclusive), when signing the ICF.~* Expected life expectance ≥ 3 months.~* Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.~* Confirmation either by histology unresectable hepatocellular carcinoma..~* BCLC stage C, and non-resectable BCLC stage B .~* No prior systemic therapy for HCC.~* Child-Pugh class A and B (≤7 points).~* At least one measurable lesion according to RECIST criteria.~* Adequate hematologic and end-organ function.~* For women of childbearing potential: agreement to remain abstinent; For men: agreement to remain abstinent.~Exclusion Criteria:~* Prior treatment with anti-PD1, anti-PD-L1 or anti-CTLA-4 antibody therapy.~* Active ongoing infection requiring therapy.~* History of severe hypersensitivity reaction to another monoclonal antibody.~* Received any live attenuated vaccine within the last 30 days.~* Other malignancy requiring treatment in the prior 5 years with the exception of locally treated squamous or basal cell carcinoma.~* Pregnant, breast feeding, or planning to become pregnant.~* Active or prior documented autoimmune or inflammatory disease with some exceptions.~* Central nervous system metastases and/or carcinomatous meningitis.~* Medical condition that requires chronic systemic steroid therapy, or any other form of immunosuppressive medication.~* Co-infection of HBV and HCV.~* Inadequately controlled arterial hypertension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AK105 and anlotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of acne vulgaris with facial involvement.~* A minimum of 20 but not more than 50 inflammatory lesions~* A minimum of 30 but not more than 100 noninflammatory lesions~* A score of 3 (Moderate) on the Investigator's Global Assessment Scale

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adapalene/Benzoyl Peroxide Gel (Type: EXPERIMENTAL): Participants were treated with adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.
- Adapalene Gel, 0.1% (Type: EXPERIMENTAL): Participants were treated with 0.1% of adapalene gel topically daily in the evening for 12 Weeks.
- Benzoyl Peroxide Gel 2.5% (Type: EXPERIMENTAL): Participants were treated with 2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
- Gel Vehicle (Type: PLACEBO_COMPARATOR): Participants were treated with gel vehicle topically daily in the evening for 12 Weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (age 18-up)admitted to inpatient cardiac unit at Massachusetts General Hospital~* Primary diagnosis of acute coronary syndrome, congestive heart failure, or arrhythmia~* Positive anxiety or depression screen during initial nursing intake interview that is performed as part of usual clinical care~* Meets criteria for clinical depression, generalized anxiety disorder, or panic disorder~Exclusion Criteria:~* Bipolar disorder~* Substance use disorder~* Psychosis~* Cognitive disorder~* Active suicidal ideation~* Medical condition with likely survival less than 6 months~* Non-English speaking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Collaborative care (Type: EXPERIMENTAL): Study care manager provides education and coordinates treatment between study psychiatrist, patient, and primary medical physician. This occurs in the hospital and by phone after discharge. Care manager may also provide phone-based therapy.
- Usual care (Type: PLACEBO_COMPARATOR): Patient's physicians are informed of diagnosis of depression/anxiety disorder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tizanidine and Superficial Cervical Block on Pain After Thyroidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologist's physiologic state I-III patients undergoing thyroidectomy~Exclusion Criteria:~* chronic pain~* bleeding disorders~* renal or hepatic insufficiency~* patients on chronic non-steroidal anti-inflammatory medications~* recurrent goiter~* emergency cases

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Group Placebo (Group P) will receive placebo 1 hour before surgery and bilateral superficial cervical block with saline 10 ml each side
- Tizanidine (Type: EXPERIMENTAL): Group Tizanidine (Group T) will receive 6 mg tizanidine 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side
- Bupivacaine (Type: ACTIVE_COMPARATOR): Group Bupivacaine will receive placebo 1 hour before surgery and bilateral superficial cervical block with %0.25 bupivacaine 10ml each side

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients younger than 24 weeks.~* Presenting a hemangioma with the following characteristics:~* Subcutaneous and/or cutaneous~* Minimum diameter of 1.5 cm on face, 3 cm outside face and 1.5 cm if it is ulcerated.~* Consent of both parents (or the person having parental authority in families)~Exclusion Criteria:~* Infant presenting contraindications for the administration of propranolol or atenolol.~* Hemangioma has been previous treated with corticosteroids, laser, cryotherapy, or only other treatments.~* Patients with an inability to participate or to follow the study treatment and assessment plan.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Weeks
- Healthy Volunteers: t

Study Arms:
- Propranolol (Type: ACTIVE_COMPARATOR): Propranolol
- Atenolol (Type: ACTIVE_COMPARATOR): Atenolol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Mindfulness-Based Exercise for Posttraumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* employed as a nurse~* PCL-C score of at least 28 with at least a score of 3 on one or more items for inclusion in the PTSD symptomatic groups (EX and CON)~* PCL-C score of 27 or lower for inclusion in the non-PTSD symptomatic group (BASE).~Exclusion Criteria:~* the inability to complete the exercise program~* a positive answer to any of the seven screening questions on the Physical Activity Readiness Questionnaire (PAR-Q)~* current use of prednisone or other forms of cortisone medication excluding cortisone in inhaled form

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Exercise Group (Type: EXPERIMENTAL): Participants who are screened positive for PTSD and participate in the series of 16 standardized, semiweekly 60-minute mindfulness-based exercise sessions. The intervention consists of stretching and balancing movements combined with breathing and a focus on mindfulness.Over the course of 8 weeks, the intensity of the exercise increases, but the sequence of the movements is the same.
- Control Group (Type: NO_INTERVENTION): Participants who are screened positive for PTSD but do not participate in the mindfulness-based exercise.
- Base Group (Type: NO_INTERVENTION): Healthy volunteers who are not screened positive for PTSD and do not participate in the mindfulness-based exercise.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of ArTiMist™ in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The patient's parent or attendant relative has provided informed consent and the patient has assented (where relevant) to participation in the trial~2. The patient is a child that weighs between 5 and 15 kg (kilogram)~3. The patient has falciparum malaria as evidenced by~   1. Thick or thin blood smears of \> 500 P falciparum per mcl (microlitre)(patients with mixed infections may be included provided \>500 P Falciparum /mcl) and /or~  2. Positive RDT (rapid diagnostic test)for malaria~4. The patient has either~   1. severe or complicated malaria as determined by the Investigator based on the WHO criteria for severity, or~  2. the patient has uncomplicated malaria but is unable to tolerate oral medication as a result of gastrointestinal complications such as vomiting or diarrhoea.~Exclusion Criteria:~1. Attending relative or parent does not provide informed consent for participation, or the child if capable does not assent to participation in the trial.~2. Ability to tolerate oral therapy~3. Patient has received any treatment with an artemisinin or quinine in the last 24 hours~4. Patient has evidence of significant co-infections (this does not include mixed Plasmodium infections).~5. Patient is allergic or intolerant to artemisinins.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ArTiMist (artemether sublingual spray) (Type: EXPERIMENTAL): None
- Intravenous Quinine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Study subjects must be adults with an established diagnosis of heart failure (New York Heart Association Class II or III) and reduced left ventricular ejection fraction (LVEF) (≤ 35%) or be healthy volunteers without heart disease.~Exclusion Criteria:~* Healthy volunteers are not eligible if they have a history diabetes mellitus, signs/symptoms of neurological disease (eg, Parkinson's Disease, multiple system atrophy, Parkinsonian syndromes), or other diseases known to affect the sympathetic nervous system.~* Subjects with New York Heart Association Class I or IV heart failure are not eligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 123I-mIBG (meta-iodobenzylquanidine (Type: EXPERIMENTAL): Single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete